Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer application for approval.

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Senior medical analyst Dr. Marc Siegel discusses advancements in artificial intelligence aimed at predicting an individual's future risk of breast cancer and the increased health risks from cannabis ...

Selumetinib is currently FDA approved for children 2 years and older with symptomatic and inoperable plexiform neurofibromas.